JPH09501440A - フラボノイド及びバイフラボノイド誘導体、その薬物的化合物並びにその抗不安活性 - Google Patents
フラボノイド及びバイフラボノイド誘導体、その薬物的化合物並びにその抗不安活性Info
- Publication number
- JPH09501440A JPH09501440A JP7506839A JP50683995A JPH09501440A JP H09501440 A JPH09501440 A JP H09501440A JP 7506839 A JP7506839 A JP 7506839A JP 50683995 A JP50683995 A JP 50683995A JP H09501440 A JPH09501440 A JP H09501440A
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- halo
- compound
- dimer
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 一般式(I) のフラボノイド化合物の効果的非毒素量を患者に投与し、もしくは一般式(I) の化合物のダイマーであるバイフラボノイドの効果的非毒素量の投与とからなる 患者の不安処理方法。 (式中、R1、R2、R3、R4、R5及びR8はH、OH、R、NO2、ハロ、OR 、NH2、NHR、NR2、COOR、COOH、CN、もしくは糖類から個別に 選択され、R6とR7は共にHであるか、もしくはR6とR7は互いに一重結合をな し;RはC1-6アルキルもしくはアルケニルである)。 2. R6とR7はともにHである請求項1に記載の方法。 3. R6とR7は互いに一重結合をなす請求項1に記載の方法。 4. R1、R2、R3、R4及びR5はH、OH並びにハロから個別に選択される 請求項3に記載の方法。 5. R1とR3はともにヒドロキシである請求項4に記載の方法。 6. 一般式(I)の化合物はクリシンである請求項5に記載の方法。 7. R1、R3及びR5は全てヒドロキシである請求項4に記載の方法。 8. 一般式(I)の化合物はアピゲニンである請求項7に記載の方法。 9.R5はOH及びハロから選択される請求項4に記載の方法。 10.R5はハロである請求項5に記載の方法。 11.一般式(I)の化合物は2’−クロロクリシン並びに2’−フルオロクリシ ンから選択される請求項10に記載の方法。 12.R2とR4は共にハロである請求項5に記載の方法。 13.一般式(I)の化合物は6、8−ジブロムクリシンである請求項12に記載の 方法。 14.R3はハロである請求項5に記載の方法。 15.一般式(I)の化台物は7−ブロムクリシンである請求項14に記載の方法。 16.バイフラボノイドダイマーは一般式(II)、 を有する請求項1に記載の方法。 (式中R1ないしR8は請求項1に与えた意味を有する)。 17.一般式(I)の各ダイマー部分におけるR1、R3及びR5はヒドロキシもし くはメトキシである請求項16に記載の方法。 18.バイフラボノイドダイマーはアメントフラボン、ギンゲチンもしくはイソギ ンゲチンである請求項17に記載の方法。 19.処理剤は実質的な鎮静効果を発揮せずに不安を減少する先行する全ての請求 項に記載の方法。 20.R1ないしR8が全てHでなく;R2及びR4ないしR8がHのときR1とR3は 共にOHでなく;さらにR4及びR6ないしR8がHのとき、R1とR3は共にOH でなくR5は4’ヒドロキシでないことを条件に、請求項1に記載の一般式(I )のフラボノイド化合物もしくは薬学的条件にかなったキャリアを添加したその ダイマーからなる薬学製剤(処方)。 21.R1、R2、R3、R4及びR5はH、OH並びにハロから個別に選択される請 求項20に記載の処方。 22.R3はハロであり、さらにR1、R2とR4及びR5はHである請求項21に記載 の処方。 23.R5はハロであり、さらにR1とR3は共にOHである請求項21に記載の処方 。 24.一般式(I)の化合物は2’−クロロクリシンまたは2’−フルオロクリシ ンである請求項23に記載の処方。 25.R2とR4は共にハロである請求項21に記載の処方。 26.一般式(I)の化合物は6、8−ジブロムクリシンである請求項25に記載の 処方。 27.R3はハロである請求項21に記載の処方。 28.一般式(I)の化合物は7−ブロムクリシンである請求項27に記載の処方。 29.バイフラボノイドダイマーは、一般式(II)、 を有する請求項20に記載の処方。 (式中、R1ないしR8及びRは請求項20に与えられた意味を有する)。 30.一般式(I)の各ダイマー部分のR1、R3及びR5はヒドロキシもしくはメ トキシである請求項29に記載の処方。 31.バイフラボノイドダイマーはアメントフラボン、ギンゲチンもしくはイソギ ンゲチンである請求項30に記載の処方。 32.一般式(I)、 のフラボノイド化合物 (式中、R1、R2、R3、R4及びR5はH、OH及びハロから個別に選択される 。R6とR7は共にH、もしくはR6とR7は互いに一重結合をなし;さらに、Rは C1-6アルキルもしくはアルキニルであり、R1、R2、R3、R4及びR5の少なく ともひとつがハロであることを条件とする)。 33.2’−クロロクリシン、2’−フルオロクリシン、6、8−ジブロムクリシ ン、さらに7−ブロムフラボンから選択される請求項32に記載のフラボノイド。 34.患者の不安処理剤としての薬剤の調製に請求項1に記載の一般式(I)のフ ラボノイド化合物もしくはそのダイマーであるバイフラボノイドを使用すること 。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939317071A GB9317071D0 (en) | 1993-08-17 | 1993-08-17 | Flavonoids |
GB9317071.0 | 1993-08-17 | ||
PCT/GB1994/001803 WO1995005169A1 (en) | 1993-08-17 | 1994-08-17 | Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09501440A true JPH09501440A (ja) | 1997-02-10 |
Family
ID=10740608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7506839A Pending JPH09501440A (ja) | 1993-08-17 | 1994-08-17 | フラボノイド及びバイフラボノイド誘導体、その薬物的化合物並びにその抗不安活性 |
Country Status (7)
Country | Link |
---|---|
US (2) | US5756538A (ja) |
EP (1) | EP0714296B1 (ja) |
JP (1) | JPH09501440A (ja) |
DE (1) | DE69429003T2 (ja) |
ES (1) | ES2167375T3 (ja) |
GB (1) | GB9317071D0 (ja) |
WO (1) | WO1995005169A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001519802A (ja) * | 1997-04-07 | 2001-10-23 | ユニバーシティ オブ ストラスクライド | ハロフラボノイド及び/又はニトロ置換フラボノイドの抗不安薬としての使用 |
JP2018505649A (ja) * | 2014-10-21 | 2018-03-01 | ブダク, メフメトBudak, Mehmet | パパベル ロエアス(Papaver rhoeas)から得られる新規分子を含む組織及び細胞染料処方 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605896A (en) * | 1992-02-25 | 1997-02-25 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities |
US5474994A (en) * | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
US5503843A (en) * | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
EP1245230A3 (en) * | 1995-06-23 | 2003-11-26 | Advanced Life Sciences Inc. | Amentoflavone as an antiviral agent |
GB9521184D0 (en) * | 1995-10-17 | 1995-12-20 | Univ Strathclyde | Flavonoids |
US5972995A (en) * | 1997-10-16 | 1999-10-26 | Children's Hospital Medical Center Of Northern California | Compositions and methods for cystic fibrosis therapy |
US7718694B2 (en) * | 1997-10-16 | 2010-05-18 | Children's Hospital & Research Center At Oakland | Compositions and methods for therapy for diseases characterized by defective chloride transport |
KR100395338B1 (ko) * | 1999-07-09 | 2003-08-19 | 김박광 | 크리신 유도체 및 이들을 포함한 혈당강하제용 조성물 |
EP1218002A4 (en) | 2000-01-24 | 2004-09-22 | Jozef S Mruk | USE OF FLAVON-8 ACETIC ACID IN VASCULAR AND CARDIOVASCULAR INTERVENTIONS AND ACUTE CORONARY SYNDROME |
US7183314B1 (en) | 2000-07-21 | 2007-02-27 | Naturon Limited | Compound for treatment of anxiety and methods of preparation and use thereof |
US7034054B2 (en) * | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
US20040152640A1 (en) * | 2001-03-23 | 2004-08-05 | Van Helvoort Adrianus Lambertus Bertholdus | Preparation for the prevention and or treatment of altered bone metabolism |
US7108868B2 (en) | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
US20030165588A1 (en) | 2002-03-01 | 2003-09-04 | Unigen Pharmaceuticals, Inc. | Identification of free-B-ring flavonoids as potent COX-2 inhibitors |
US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
EP2108370A1 (en) * | 2002-04-30 | 2009-10-14 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
US8945518B2 (en) * | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
US8034387B2 (en) * | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
US6884783B2 (en) | 2002-05-03 | 2005-04-26 | Unigen Pharmaceuticals, Inc. | 7-Hydroxy chromones as potent antioxidants |
US6740677B2 (en) | 2002-08-19 | 2004-05-25 | Hong Xue | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids |
MXPA05004247A (es) * | 2002-10-22 | 2005-10-18 | Jenken Biosciences Inc | Cromonas y derivados de cromona y usos de los mismos. |
CA2521429A1 (en) | 2003-04-04 | 2004-10-21 | Unigen Pharmaceuticals, Inc. | Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care |
CN1845750B (zh) * | 2003-09-02 | 2014-05-07 | 尤尼根公司 | 用于预防及治疗认知衰退和年龄相关的记忆障碍的无取代b环类黄酮和黄烷混合物的组合物 |
KR100610562B1 (ko) * | 2004-06-28 | 2006-08-08 | 재단법인서울대학교산학협력재단 | 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물 |
BRPI0518322A2 (pt) * | 2004-11-16 | 2008-11-18 | Limerick Neurosciences Inc | composiÇço, kit, e, mÉtodos para tratar uma condiÇço, para reverter um efeito no sistema nervoso central de um agente, para tratar um animal de dor, e para controlar dor crânica |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
TWI454261B (zh) | 2007-01-09 | 2014-10-01 | Unigen Inc | 作為治療劑之色酮類 |
AU2008257437A1 (en) * | 2007-02-14 | 2008-12-04 | Mars, Incorporated | Neurogenic compounds |
US7722522B2 (en) * | 2008-02-11 | 2010-05-25 | Gregg Alan Klang | Brace providing focused energy for medical therapy |
BRPI0801239A2 (pt) * | 2008-04-01 | 2009-11-17 | Ache Lab Farmaceuticos Sa | uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase |
US20100075926A1 (en) * | 2008-07-23 | 2010-03-25 | Li-Huei Tsai | Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival |
CN102143744B (zh) * | 2008-07-25 | 2016-08-31 | 爱默蕾大学 | 7,8-二羟基黄酮及其衍生物在制备治疗抑郁的药物中的用途 |
WO2011156479A2 (en) | 2010-06-09 | 2011-12-15 | Emory University | Trkb agonists and methods of use |
DK2734510T3 (en) | 2011-07-22 | 2019-03-04 | Massachusetts Inst Technology | CLASS I-HISTONDEACETYLASES (HDAC) ACTIVATORS AND APPLICATIONS THEREOF |
US9593125B2 (en) | 2012-07-27 | 2017-03-14 | Emory University | Heterocyclic flavone derivatives, compositions, and methods related thereto |
US10123991B2 (en) | 2015-05-15 | 2018-11-13 | Global Biolife Inc. | Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders |
CN108250172A (zh) * | 2017-11-22 | 2018-07-06 | 中国科学院西北高原生物研究所 | 一种具有抗焦虑功效的化合物及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903266A (en) * | 1972-05-03 | 1975-09-02 | Ralph C Robbins | Compositions and methods for disaggregating blood cells |
US4241069A (en) * | 1979-09-04 | 1980-12-23 | Miles Laboratories, Inc. | 3-Methylene flavanones and 3-methylene chromanones |
EP0558245A1 (en) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors |
-
1993
- 1993-08-17 GB GB939317071A patent/GB9317071D0/en active Pending
-
1994
- 1994-08-17 US US08/586,796 patent/US5756538A/en not_active Expired - Lifetime
- 1994-08-17 WO PCT/GB1994/001803 patent/WO1995005169A1/en active IP Right Grant
- 1994-08-17 EP EP94924912A patent/EP0714296B1/en not_active Expired - Lifetime
- 1994-08-17 DE DE69429003T patent/DE69429003T2/de not_active Expired - Lifetime
- 1994-08-17 ES ES94924912T patent/ES2167375T3/es not_active Expired - Lifetime
- 1994-08-17 JP JP7506839A patent/JPH09501440A/ja active Pending
-
1997
- 1997-09-29 US US08/939,975 patent/US6004998A/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001519802A (ja) * | 1997-04-07 | 2001-10-23 | ユニバーシティ オブ ストラスクライド | ハロフラボノイド及び/又はニトロ置換フラボノイドの抗不安薬としての使用 |
JP2018505649A (ja) * | 2014-10-21 | 2018-03-01 | ブダク, メフメトBudak, Mehmet | パパベル ロエアス(Papaver rhoeas)から得られる新規分子を含む組織及び細胞染料処方 |
Also Published As
Publication number | Publication date |
---|---|
EP0714296A1 (en) | 1996-06-05 |
WO1995005169A1 (en) | 1995-02-23 |
ES2167375T3 (es) | 2002-05-16 |
DE69429003D1 (de) | 2001-12-13 |
DE69429003T2 (de) | 2002-07-11 |
US5756538A (en) | 1998-05-26 |
US6004998A (en) | 1999-12-21 |
EP0714296B1 (en) | 2001-11-07 |
GB9317071D0 (en) | 1993-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09501440A (ja) | フラボノイド及びバイフラボノイド誘導体、その薬物的化合物並びにその抗不安活性 | |
CN101641013A (zh) | 核受体结合剂 | |
TWI387456B (zh) | 用於治療瘧疾之二茂鐵氯奎(ferroquine)及黃花蒿素(artemisinin)衍生物之組合 | |
AU4490900A (en) | Beta-carboline pharmaceutical compositions | |
PL180465B1 (pl) | Kompozycja farmaceutyczna zawierajaca trans-5-chloro-2-metylo-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pirol PL PL PL | |
HUE032009T2 (en) | Veterinary preparations for topical veterinary use | |
DE69929440T2 (de) | Zusammensetzungen zur behandlung chronischer lymphatischer leukämie | |
EP0278161B1 (en) | Ketone derivatives as medicaments for the treatment or prevention of the withdrawal syndrome | |
EP1841437A2 (en) | 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity | |
CN100438862C (zh) | 辅酶q作为活性成分的经粘膜给药的组合物 | |
DE60221425T2 (de) | Substituierte tetrazyklische pyrrolochinolonderivate als phosphodiesterase-inhibitoren | |
JP4745468B2 (ja) | 不安の治療に対するニトロフラボノイドの使用 | |
DE69936186T2 (de) | Dihydroartemisinin-Formulierung zur Behandlung von verschiedenen Typen von Malaria | |
MX9307079A (es) | Mejoras en composiciones farmaceuticas para el tratamiento de trastornos funcionales de las vias intestinales y mejoras en un procedimiento para la preparacion de dichas composiciones. | |
KR100623322B1 (ko) | 경구투여용 항말라리아 배합 제제 및 그의 제조방법 | |
DE3736866A1 (de) | Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz | |
JP2001507672A (ja) | Cis―縮合シクロペンテノ―1,2,4―トリオキサン誘導体を含有する抗マラリア組成物 | |
CN114929224A (zh) | 治疗肝性脑病的新药物 | |
CA2541293A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia | |
CN106279164B (zh) | 5型磷酸二酯酶抑制剂及其应用 | |
JP2003026567A (ja) | 補酵素qを有効成分とする粘膜投与用組成物 | |
DE3930282A1 (de) | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit | |
Israel et al. | Pyrido [3, 2-g] pteridines. 2. Synthesis and growth-inhibitory evaluation of some 10-substituted 3H, 10H-2, 4-dioxopyrido [3, 2-g] pteridines (9-azaisoalloxazines) | |
DE102006022908A1 (de) | Verwendung von Chinolonderivaten als antiprotozoäre Mittel und in Kombinationspräparaten | |
Buschmann et al. | Use of sodium channel blockers for the treatment of preterm labor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040706 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051011 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051220 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060406 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060704 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061031 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061116 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20061207 |